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Abstract
Purpose PET can image neuroinflammation by targeting the
translocator protein (TSPO), which is upregulated in activated
microglia. The high nonspecific binding of the first-generation
TSPO radioligand [11C]PK-11195 limits accurate quantifica-
tion. [18F]GE-180, a novel TSPO ligand, displays superior
binding to [11C]PK-11195 in vitro. Our objectives were to:
(1) evaluate tracer characteristics of [18F]GE-180 in the brains
of healthy human subjects; and (2) investigate whether the
TSPO Ala147Thr polymorphism influences outcome
measures.
Methods Ten volunteers (five high-affinity binders, HABs,
and five mixed-affinity binders, MABs) underwent a dynamic
PET scan with arterial sampling after injection of [18F]GE-
180. Kinetic modelling of time–activity curves with one-
tissue and two-tissue compartment models and Logan graph-
ical analysis was applied to the data. The primary outcome
measure was the total volume of distribution (VT) across var-
ious regions of interest (ROIs). Secondary outcome measures
were the standardized uptake values (SUV), the
distribution volume and SUV ratios estimated using a
pseudoreference region.
Results The two-tissue compartment model was the best mod-
el. The average regional delivery rate constant (K1) was
0.01 mL cm−3 min−1 indicating low extraction across the
blood–brain barrier (1 %). The estimated median VT across
all ROIs was also low, ranging from 0.16 mL cm−3 in the
striatum to 0.38 mL cm−3 in the thalamus. There were no
significant differences in VT between HABs andMABs across
all ROIs.
Conclusion A reversible two-tissue compartment model fitted
the data well and determined that the tracer has a low first-pass
extraction (approximately 1 %) and low VT estimates in healthy
individuals. There was no observable dependency on the rs6971
polymorphism as compared to other second-generation TSPO
PET tracers. Investigation of [18F]GE-180 in populations with
neuroinflammatory disease is needed to determine its suitability
for quantitative assessment of TSPO expression.
Keywords Positron emission tomography (PET) . GE180 .
Translocator protein (TSPO) . Kinetic analysis .
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Introduction
The translocator protein (TSPO) is a mitochondrial transporter
involved in varied intracellular processes, but its expression in
the central nervous system (CNS) is relatively low under nor-
mal physiological conditions [1]. However, activation of
microglial cells caused by inflammatory stimuli results in sig-
nificant upregulation of TSPO expression [2]. TSPO quanti-
fication with PET provides a measure of intrinsic neuroin-
flammation in a variety of CNS diseases. Early PET studies
used the isoquinoline [11C]PK-11195 to measure TSPO
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binding and detected elevations across a range of conditions
including multiple sclerosis [3], Huntington’s disease [4],
Alzheimer’s disease [5, 6], traumatic brain injury [7] and isch-
aemic stroke [8]. However, the use of [11C]PK-11195 is lim-
ited by a high nonspecific signal, making nonstandard ap-
proaches to data analysis necessary [9]. In addition, because
11C has a half-life of 20.3 min, the use of [11C]PK-11195 is
restricted to locations with an on-site cyclotron.
A number of second-generation TSPO ligands have been
developed recently with the promise of improved signal-to-
noise ratio and greater specific binding. [18F]GE-180 is a nov-
el fluorinated radiotracer that binds to the TSPO with high
affinity [10]. Developed from a series of tricyclic indoles,
[18F]GE-180 has demonstrated superior specific binding af-
finity to [11C]PK-11195 in animal models of acute neuroin-
flammation [11] and stroke [12]. The 18F radiolabel, with a
half-life of 109.8 min, also makes [18F]GE-180 more suitable
than 11C-based compounds for long-distance distribution, en-
abling widespread clinical use.
Other second-generation TSPO radiotracers (e.g.
[11C]PBR-28, [18F]PBR-06, [11C]-DAA1106, [11C]-
DPA713, [18F] FEPPA) show binding affinities influenced
by a TSPO polymorphism expressed by individuals and have
been classified as high-affinity binders (HABs), mixed-
affinity binders (MABs) and low-affinity binders (LABs)
[13]. Expression of the TSPO Ala147Thr polymorphism re-
sults in MAB or LAB depending on whether one or two cop-
ies are present [14]. Here, we report a study in healthy subjects
using [18F]GE-180 PET imaging. The primary aim was to
investigate tracer kinetics and quantification in healthy human
subjects. The secondary aim was to investigate whether there
were differences in binding between HABs and MABs.
Materials and methods
Human subjects
This study was approved by the Westminster Research Ethics
Committee, London (13/LO/1596), the Riverside Research
Ethics Committee (13/LO/1916), and the Administration of
Radioactive Substances Advisory Committee (no. 631/336/
30788). Research was conducted in accordance with the prin-
ciples of the Declaration of Helsinki [15]. All subjects gave
written, informed consent.
Ten healthy volunteers (seven men), mean age 41
± 9 years (range 28 – 56 years), mean weight 81.8
± 13 kg, were included in the study. A screening assess-
ment was carried out that included full medical and
drug history, blood pressure, height, weight, Allen’s test
for patency of the ulnar anastomosis, and the Structured
Clinical Interview for DSM disorders (SCID). Blood
samples were taken for analysis of full blood count,
renal profile, clotting screen and TSPO genotyping.
Exclusion criteria included pregnancy, a history of prior
or current psychiatric or neurological disease, abuse of
alcohol or drugs and contraindication to arterial line
placement.
TSPO genotyping
DNAwas extracted using a Qiagen QIAmp DNA blood mini
kit. TSPO genotyping of the c.439A >G (p.Thr147A1a) (SNP
rs6971) was performed using a TaqMan allelic discrimination
assay. LABs (one subject) were excluded from the imaging
component of the study. During the study design it was felt
that on ethical and economical grounds LABs should not be
exposed to this novel tracer and instead that the focus should
be on MABs and HABs. Of the ten subjects eligible for im-
aging, five were HABs and five were MABs.
Synthesis of [18F]GE-180
[18F]-Fluorine was produced by the 18O(p,n)18F nuclear reac-
tion on a GE PETtrace 8 cyclotron (The Grove Centre,
Amersham, UK). All radiochemistry was performed on a
GE FASTlab synthesizer with single-use cassettes. The aver-
age synthesis timewas 43mins, radiochemical yield was 43%
and purity was greater than 95 % [16]. The radiotracer was
manufactured by GE Healthcare (The Grove Centre,
Amersham, UK), transported to Hammersmith Hospital,
London, and used within 8 h of manufacture.
Positron emission tomography scanning and image
reconstruction
All subjects were scanned at the Clinical Imaging Facility,
Imperial College London, Hammersmith Hospital. Prior to
PET scanning, an arterial cannula was inserted under local
anaesthesia (2 % lidocaine) into the radial artery to allow
arterial blood sampling. An antecubital venous cannula was
inserted for radiotracer administration.
PETstudies were performed on a Biograph 6 (six-slice CT)
scanner after administration of 182 ± 3.1 MBq via intravenous
bolus injection over 10 s followed by a 10-mL saline flush. A
low-dose CT scan preceded the PET acquisition to allow cor-
rection for tissue attenuation. Emission data were then ac-
quired over 90 min in list mode and reconstructed as 24 tem-
poral frames (6 × 15, 3 × 60, 5 × 120, 5 × 300, 5 × 600 s) using
filtered back-projection (matrix size 168 × 168, zoom 2.6, 5-
mm gaussian filter, pixel size 1.56 × 1.56, slice thickness
3 mm) with and without attenuation correction. Standard cor-
rections for scatter, decay and random counts were applied.
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Whole-blood, plasma activity and parent fraction of [18F]
GE-180
Arterial blood activity was measured every second for
the first 15 min of the 90-min scan using an automated
blood sampling system (ABSS Allog, Mariefred,
S w e d e n ) c o n n e c t e d t o t h e s u b j e c t v i a a
1.5 m × 1.0 mm diameter polytetrafluoroethylene line
(blood withdrawal rate 2.5 ml/min). In addition, blood
samples (10 mL) were collected manually from the ra-
dial artery at 0, 5, 10, 15, 30, 50, 70 and 90 min to
assay whole-blood and plasma activity. Plasma was ob-
tained by centrifugation for 3 min at 1,800 g. Activity
in whole blood and plasma was measured in a
CAPRAC-t well counter over 10 – 60 s. The first
15 min of continuous whole-blood activity was com-
bined with the activity from discrete samples to gener-
ate the whole-blood activity curve for use in data
modelling. The continuous plasma-to-blood ratio was
estimated using a constant model and a total plasma
activity curve was obtained by correcting the whole-
blood curve for this partition between plasma and
blood.
The parent fraction of [18F]GE-180 was measured by
high-performance liquid chromatography (Agilent 1,100
and 1,260 series) of discrete plasma samples (3.5 mL).
The parent fraction was fitted to a single exponential
plus a constant model. The total plasma activity was
multiplied by this parent fraction and then smoothed
post peak by fitting to a triexponential function to gen-
erate an arterial parent plasma input function. A delay
correction of up to +30 s was applied to the input
function prior to fitting the kinetic modelling. This
was performed to account for delay in the 1.5-m tube
(28.3 s) and delay between the radial artery and the
brain.
Magnetic resonance imaging
To provide additional anatomical information to aid analysis
of the PET data, each subject underwent a structural T1-
weighted MRI scan on a Siemens Verio 3-T scanner (matrix
size 256 × 256, voxel size 1 × 1 × 1 mm , TR 9.63 ms, TE
4.74 ms, flip angle 9°).
Data analysis
A high level overview of the data analysis is provided in
Fig. 1. We used the PET data analysis and kinetic modelling
toolkit, MIAKAT™ (www.miakat.org), which incorporates
software from SPM5 (Wellcome Trust Centre for
Neuroimaging) and FSL (FMRIB, University of Oxford)
[17]. The brain was initially extracted from the T1-weighted
MR images. The CIC neuroanatomical atlas [18] was
nonlinearly registered to the individual’s extracted brain in
order to generate a personalized set of anatomically
parcellated regions [18]. Frame-by-frame motion correction
of the dynamic (without attenuation correction) PET data
was performed using mutual information coregistration of
the individual frames to a reference frame. An average
motion-corrected PET image was generated and used for
coregistration with the T1-weighted MR image. Finally, re-
gional tissue time–activity curves (TACs) were generated for
each region of interest (ROI) defined from the CIC atlas that
had been transformed into each individual’s image space.
Datasets were analysed with a one-tissue compart-
ment (1TC) model and a two-tissue compartment
(2TC) model and the Logan graphical method, using
the metabolite-corrected plasma input function as previ-
ously described [19] with a fixed 5 % blood volume
correction. The primary outcome measures were the
radioligand delivery rate constant (K1; mL cm
−3
min−1), total distribution volume (VT: mL cm
−3), and
standardized uptake values (SUV). The SUV ratio
(SUVR) and distribution volume ratio (DVR) were esti-
mated using the cortical grey matter as a pseudo refer-
ence region. This region was chosen as there is no true
reference region for TSPO, but the cortical grey matter
has been used as a reference in previous work as
healthy brain usually shows low TSPO expression in
this region [20].
Time stability analysis
To investigate the stability of VT over different scan durations,
a time stability analysis was performed by analysing data for
total time windows that ranged between 40 and 90 min in 10-
min increments.
Statistical analysis
The Akaike information criterion (AIC) was used to
select the most appropriate compartment model [21],
where lower AIC was indicative of a more parsimonious
model. To compare characteristics between the genetic
groups (HAB/MAB), Fisher’s exact test (gender) and
the Mann Whitney U test (age, weight, injected dose)
were used. To evaluate differences in TACs for blood
data between the genetic groups, a repeated measures
analysis of variance (ANOVA) was used with time as
the within-subjects factor and genotype as the between-
subjects factor. A repeated measures ANOVA was also
used to compare outcome measures across multiple
ROIs, where ROI was used as the within-subjects factor.
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Results
Injection of [18F]GE-180 caused no pharmacological effects
based on patient reports, blood pressure, pulse, respiration rate
and oxygen saturation after radioligand administration. There
were no significant differences in gender, age or weight be-
tween HABs and MABs. With regard to correlations between
age and the principal outcome measure, there were no signif-
icant correlations between age and VT in either HABs and
MABs in any of the ROIs s tudied (Spearman ’s
rho = −0.3 – 0.7 p = 0.188 – 0.873 in HABs; Spearman’s
rho = 0.1 – 0.8, p = 0.104 – 0.94 in MABs). There were also
no significant relationships between age and outcome mea-
sures when added as a covariate in the repeated measures
ANOVA. Demographic data are provided in Supplementary
Table 1.
Plasma data
In plasma, the concentration of [18F]GE-180 peaked at
about 45 s and then showed a rapid decrease (Fig. 2a).
The fraction of unchanged [18F]GE-180 over time is
shown in Fig. 2b. The parent compound accounted for
65.0 – 81.7 % (range across subjects) of the total con-
centration in plasma at 30 min, and 57.3 – 78.3 % at
90 min. Three polar radioactive metabolites were iden-
tified over the course of the 90 min scanning window
(<10 % of parent compound). The plasma-to-blood ratio
remained constant at about 1.69 (Fig. 2c) across sub-
jects. There were no significant differences in profiles
of plasma over blood (F(1,48) = 0.407, p = 0.541), parent
fraction (F(1,48) = 0.871, p = 0.378) or parent in plasma
between genetic groups (F(1,48) = 0.130, p = 0.728).
There was no interaction of genotype with time for
any of these profiles (p > 0.204). The parent in plasma
p ro f i l e s fo r HABs and MABs a r e shown in
Supplementary Fig. 1.
Tissue data
The concentration of the ligand in the brain peaked at
around 1 min and then showed rapid washout in all
subjects. Group-averaged tissue TACs for the frontal
grey matter and thalamus are shown in Fig. 3a, b. A
60 – 90-min SUV image in a representative MAB sub-
ject is shown in Fig. 3c. Overall, there was low uptake
of the tracer in brain with images being dominated by
signal from blood vessels. There were no significant
differences in SUV curves between genetic groups
(F(1,48) = 1.396, p = 0.271). There was no interaction
of genotype with time (P = 0.684).
Kinetic analysis
The results of the kinetic modelling are shown in Table 1. The
2TC model was superior to the 1TC model as judged by a
Fig. 1 Overview of data analysis. The MIAKAT™ analysis toolkit was used for image processing (a), blood data processing (b) and kinetic modelling
(c) of the PET data
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lower AIC in all ROIs except the striatum. Example model fits
for the 1TC and 2TC models are shown in Fig. 4a in a repre-
sentative MAB subject. The first 10 min of Fig. 4a and Fig. 4c
are shown in more detail in Supplementary Fig. 2. The 2TC
model generally showed a good fit to the data except for an
initial small mismatch in the blood volume peak, which was
considered not to have affectedVTestimates.Whenwe includ-
ed the 2TC-fit model, it did not outperform the 2TC-fix based
on the AIC. Blood volume estimates ranged from 6.3 % to
10.5 % (mean 8.4 %) across all ROIs. Therefore, the 2TC-fix
was selected as the model to use for further analysis and gave
average rate constants (across all regions and subjects) of
K 1 = 0 . 013 mL cm
− 3 m in − 1 , k 2 = 0 . 229 m in
− 1 ,
k3 = 0.035 min
−1 and k4 = 0.010 min
−1, resulting in
VT = 0.311 mL cm
−3 (Table 1).
K1 was low across all ROIs in all subjects, indicating low
extraction across the blood–brain barrier (BBB). This is con-
sistent with the low tissue uptake observed in the images and
the predominance of the vasculature structures. There was no
significant effect of genetic group on any of the four rate
Fig. 2 Blood data. aWhole
blood (red) and parent in plasma
(black) curves for one subject. b
The fraction of unchanged parent
compound over time for high-
affinity binders (HAB, red) and
mixed-affinity binders (MAB,
blue). c Plasma-to-blood ratio
over time for HABs and MABs.
Values are plotted in b and c as
means ± standard error of the
mean
Fig. 3 Imaging data. Time–
activity curves (TACs) are shown
for high-affinity binders (HAB)
and mixed-affinity binders (MAB)
in the frontal grey matter (a) and
thalamus (b). Standardized
uptake values (SUV) are plotted
as mean ± standard error of the
mean. c SUV image calculated
from the 60 – 90-min PET frames
superimposed on the coregistered
T1-weighted MR image in a
representative MAB subject
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constants. The Logan graphical method was also used to esti-
mate the VT in each ROI (Table 1). A representative plot is
shown in Fig. 4b. Pooled VT estimates from the 2TC model
were positively correlated with VT from the Logan method
(Pearson’s r = 0.630, p < 0.0001; regression equation
VT(Logan) = 0.3 × VT(2TC) + 0.19). The tissue TAC minus
the whole-blood radioactivity curve demonstrated that ap-
proximately 20 % of the activity in a typical ROI came from
blood (Fig. 4c).
Time stability analysis and outcome measures
The time stability analysis of the 2TC model demonstrated an
increasing VT for each successive time window analysed
(shown for two ROIs in Fig. 4d). A comparison of six out-
come measures for a number of ROIs is shown in Fig. 5. For
all six outcome measures, no significant effect of genetic
group was found (p > 0.186), nor was there any interaction
between genetic group and ROI (p = 0.468).
Table 1 Parameter estimates and model fits
Model Region K1 (mL/min) k2 (/min) k3 (/min) k4 (/min) VT (mL/cm
3) Distribution
volume ratio
AIC
winsa
1TC Frontal
lobe
0.00472 (0.0041 –
0.006)
0.0271 (0.023 –
0.028)
0.171 (0.15 –
0.22)
0.939 (0.94 – 0.95) 2/10
Parietal
lobe
0.00513 (0.004 –
0.0061)
0.027 (0.024 –
0.028)
0.19 (0.16 –
0.22)
0.969 (0.96 – 1) 1/10
Temporal
lobe
0.00514 (0.0048 –
0.006)
0.0266 (0.025 –
0.028)
0.182 (0.17 –
0.24)
1.04 (1 – 1) 0/10
Occipital
lobe
0.00621 (0.0057 –
0.0074)
0.03 (0.025 –
0.032)
0.214 (0.19 –
0.25)
1.12 (1.1 – 1.2) 0/10
Thalamus 0.00555 (0.0046 –
0.0058)
0.0261 (0.024 –
0.028)
0.182 (0.17 –
0.24)
1.03 (0.96 – 1.1) 0/10
Striatum 0.00358 (0.003 –
0.0046)
0.0241 (0.021 –
0.025)
0.155 (0.14 –
0.2)
0.826 (0.78 – 0.89) 8/10
Cerebellum 0.00656 (0.0054 –
0.0076)
0.0339 (0.034 –
0.034)
0.178 (0.16 –
0.22)
0.968 (0.91 – 1) 0/10
2TC Frontal
lobe
0.0102 (0.0089 –
0.013)
0.195 (0.15 – 1.6) 0.0301 (0.024 –
0.15)
0.00653 (0.004 –
0.017)
0.346 (0.26 –
0.5)
0.984 (0.96 – 1.2) 8/10
Parietal
lobe
0.0116 (0.011 –
0.014)
0.192 (0.15 –
0.25)
0.0334 (0.025 –
0.039)
0.00873 (0.0045 –
0.014)
0.33 (0.31 –
0.42)
1.01 (0.98 – 1.1) 9/10
Temporal
lobe
0.0143 (0.012 –
0.032)
0.217 (0.16 – 1.3) 0.0348 (0.03 –
0.15)
0.00927 (0.0063 –
0.016)
0.306 (0.27 –
0.42)
0.958 (0.93 – 1) 10/10
Occipital
lobe
0.0238 (0.019 –
0.031)
0.385 (0.2 – 0.62) 0.0395 (0.036 –
0.054)
0.0101 (0.0062 –
0.014)
0.35 (0.3 –
0.52)
1.07 (0.97 – 1.1) 10/10
Thalamus 0.0118 (0.011 –
0.014)
0.16 (0.14 – 0.2) 0.0315 (0.026 –
0.042)
0.00881 (0.0062 –
0.012)
0.376 (0.28 –
0.41)
0.922 (0.81 – 1.1) 10/10
Striatum 0.00413 (0.0033 –
0.0088)
1.14 (0.66 – 1.7) 4.89 (0.62 – 9.1) 0.14 (0.027 – 0.21) 0.155 (0.14 –
0.22)
0.451 (0.41 – 0.71) 2/10
Cerebellum 0.0224 (0.016 – 1.3) 0.319 (0.23 – 78) 0.0331 (0.029 –
0.091)
0.0113 (0.0084 –
0.018)
0.281 (0.25 –
0.33)
0.916 (0.69 – 0.98) 10/10
Logan Frontal
lobe
0.265 (0.23 –
0.33)
0.931 (0.92 – 0.97)
Parietal
lobe
0.284 (0.23 –
0.35)
0.996 (0.93 – 1)
Temporal
lobe
0.312 (0.24 –
0.36)
1.01 (0.95 – 1.1)
Occipital
lobe
0.34 (0.3 –
0.39)
1.14 (1.1 – 1.2)
Thalamus 0.3 (0.26 –
0.31)
0.991 (0.98 – 1)
Striatum 0.25 (0.21 –
0.29)
0.844 (0.7 – 0.92)
Cerebellum 0.29 (0.24 –
0.3)
0.99 (0.91 – 1)
Data are presented as medians (interquartile ranges)
a For the 1TC model versus the 2TC model, the data shown are the proportions of the ten subjects for whom the model was the more parsimonious
(defined as having the lower AIC)
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Discussion
Here we describe the characterization and quantification of the
novel TSPO tracer [18F]GE-180 for the first time in the normal
healthy human brain. We generated arterial parent plas-
ma and whole-blood input functions and fitted brain
TACs to 1TC and 2TC kinetic models and Logan
graphical analysis to generate outcome measures across
regions and individuals. The following key outcome
measures were generated from the analysis: K1, VT,
SUV, DVR and SUVR with the cortical grey matter as
a pseudo reference region. In addition, we investigated
whether the TSPO Ala147Thr polymorphism in the
TSPO binding site influenced these outcome measures
[14, 22].
There was consistent and stable metabolism of [18F]GE-
180 parent compound across all individuals. There was no
difference in blood or plasma activity between the two geno-
types and there were only moderate levels of detectable me-
tabolites in all individuals with 70 % of the intact parent tracer
remaining at 90 min. SUV images across all individuals
demonstrated low uptake of the tracer in brain tissue with
significant tracer activity apparent in the blood compartments
of the brain. The low brain uptake could reduce the signal-to-
noise ratio for this tracer and might mean that variation in the
activity within the blood across the groups could have biased
results. In addition, the low uptakemight make the tracer more
susceptible to showing increased uptake when there is BBB
breakdown.
Analysis of the tracer compartment models showed that the
reversible 2TC model provided the best overall fit in the ma-
jority of cases. There was a small discrepancy in the model fit
at the initial sharp peak of the curve, i.e. <5 min of data ac-
quisition. It is possible that this may be due to increased dis-
persion of [18F]GE-180 in the vascular bed, although this is
difficult to quantify precisely. In addition, the 1.5-m line that
was used from the radial artery to the arterial blood detection
machine may have affected the model fit. However, this dis-
crepancy should not significantly affect the estimation ofVTas
this is based on the integral of the impulse response function
(i.e. integral/area under the curve of plasma input function)
[23].K1 could be affected by dispersion but would still remain
Fig. 4 Kinetic modelling and
time stability analysis. aModel
fits are shown for one-tissue
compartment model (reversible
1TC, dashed line) and two-tissue
compartment model (reversible
2TC, red line) against a time–
activity curve (black dots) for the
parietal lobe. b Logan plot (black
dashed line the most linear
portion of the curve) for the same
time–activity curve as in a. c
Parietal lobe time–activity curve
(solid line), 5 % whole-blood
activity curve (red line) and the
curve of the difference between
the two curves (dashed line)
highlights the significant
contribution of blood signal to the
time–activity curve. d Estimates
of two-tissue compartment model
VT calculated for 40 – 90-min
scan windows in 10-min
increments plotted as the absolute
percentage difference compared
to the final 90-min VT for the
parietal lobe and cerebellum grey
matter regions of interest. The
values plotted are means
± standard error of the mean
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small after any correction and therefore the interpretation of
low brain delivery of this tracer is still valid.
Using the 2TC model, the initial rate constant, K1, was
consistently low, suggesting a low extraction fraction and de-
livery into brain tissue. Theoretically, there could be a number
of reasons for this. First, the low K1 could be due to low
lipophilicity. However, preclinical work has suggested that
this tracer is relatively lipophilic (logD at pH 7.4 is 2.95),
making this unlikely. Second, [18F]GE-180 could be a sub-
strate for xenobiotic pumps at the BBB such as the three major
ABC transporters, p-glycoprotein (ABCB1), multidrug resis-
tance protein 1 (ABCC1) and mitoxantrone resistance protein
(ABCG2), as can be seen with other tracers with low BBB
penetration [24]. Third, the low K1 could be due to increased
plasma protein binding, although the relationship here is com-
plex and high plasma protein binding does not always lead to
low brain penetration. Most molecules to a greater or lesser
extent bind to human serum albumin and some tracers also
bind to alpha1-acid glycoprotein [25]. However, in the case of
[18F]GE-180, the binding affinity to these or other plasma
proteins may be considerable. A limitation of this study was
that the protein binding of [18F]GE-180 was not measured.
However, in vitro work suggests that in humans the plasma
free fraction is approximately 3 %.
The median volume of distribution of [18F]GE-180 using
the 2TC model across all subjects and brain regions ranged
from 0.16 to 0.38 mL cm−3. There was little variability across
brain regions.VTestimates were lower than those observed for
some other second-generation TSPO tracers (e.g. 4.1 ± 1.6 mL
cm−3 for [11C]-PBR-28 in grey matter [26], and
0.72 – 1.06 mL cm−3 for [11C]PK-11195 [27]).
Our time stability analysis demonstrated that VT did not
reach a stable level but continuously increased over the 90-
min scanning window. This might have led to underestimation
of VT. A scan time of 90 min was originally selected based on
preclinical studies and on consideration of what would be
acceptable to the individual subjects. However, our results
suggest that a longer scanning duration might give a more
‘stable’ VT estimate. This ongoing increase in VT could have
been caused by the accumulation of radiometabolites in the
brain. However, only modest levels of metabolites were de-
tected in the blood, and earlier preclinical work demonstrated
Fig. 5 Outcome measures. Six
outcome measures for seven
regions of interest (red high-
affinity binders, blue mixed-
affinity binders). a Two-tissue
compartment model volume of
distribution (2-TC VT). b Volume
of distribution estimated using
Logan plot (Logan VT). c
Distribution volume ratio from
the two-tissue compartment
model using cortical grey matter
as a reference region (2-TC DVR).
d Distribution volume ratio
estimated using Logan plot and
cortical grey matter as a reference
region (Logan DVR). e 60 –
90 min standardized uptake
values (e SUV). f 60 – 90 min
standardized uptake value ratios (f
SUVR) using cortical grey matter
as a reference region
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very low penetration of any metabolite into the brain with 94 %
parent at 60 min [28]. Metabolites have not formally been iden-
tified, but all those observed in this study were more polar than
the parent. It is believed that the two main routes of metabolism
are O-demethylation and hydroxylation of the aliphatic ring
[28]. Other metabolites could be a combination of the two pro-
cesses or hydroxylation at different sites. The question of accu-
mulation of metabolites in the brain is most relevant when brain
uptake is high, which was not the case here. It is also worth
noting that these time stability results are consistent with those
from other TSPO tracers which also do not achieve a stable
estimate within a 2-h scanning window, e.g. [11C]PBR28 [19].
No evidence of an effect of TSPO genotype on any of our
outcomemeasures was found. No differences in K1, VT, DVR,
SUVor SUVR between MABs and HABs were found. This
was an unexpected finding, as in vitro work with cold GE-180
displacing [3H]PK11195 has shown a binding affinity of 15:1
between HABs and LABs (D. Owen, personal communica-
tion). Although we did not acquire PET scans in LABs, we
would still have expected to see differences in the outcome
measures between HABs and MABs. Our expectation was
that MABs would show an intermediate binding relative to
that in HABs, i.e. around 50 % of the binding in HABs [13].
The fact that we did not observe such a difference in vivo may
have been a consequence of the low uptake seen with this
tracer. Genotype effects may be found in other groups, for
example older individuals or diseased individuals in whom
we may expect microglial TSPO expression to be higher.
We did consider the effect that increasing age of the subjects
could have had on TSPO binding, as has been shown previ-
ously [29], but we did not find any correlations between age
and VT in any of the ROIs.
In summary, we report the first PETstudies of [18F]GE-180
in humans. Administration of the tracer was safe and the scan
was tolerated well by all subjects. A reversible 2TC model
fitted the data well and determined that the tracer has a low
first-pass extraction (about 1 %) and low VT estimates in our
healthy subjects. There was no observable dependency on the
rs6971 polymorphism as compared to other second-
generation TSPO PET tracers. A low first-pass extraction
combined with a tissue signal with a relatively large blood
component suggests similarities to [11C]PK-11195 in vivo.
However, more work with [18F]GE-180 in humans would be
informative and should include studies in patients with
neuroinflammatory conditions to assess signal in the presence
of upregulated TSPO, studies in subjects of various ages and a
competition study to more clearly delineate specific binding.
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